FINWIRES · TerminalLIVE
FINWIRES

Agios Gets EU Approval for Pyrukynd in Thalassemia

By

Agios Pharmaceuticals (AGIO) said Friday the European Commission granted marketing authorization for Pyrukynd to treat adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.

The oral therapy received orphan medicinal product designation in the European Union.

The approval was based on results from the two phase 3 clinical trials evaluating the medicine in adults with thalassemia, Agios said.

The company added that its partner, Avanzanite Bioscience, will continue to commercialize and distribute Pyrukynd across Europe.

Price: $28.58, Change: $-0.21, Percent Change: -0.73%

Related Articles

Wire

Baird Adjusts Agilent Technologies Price Target to $156 From $155, Maintains Outperform Rating

Agilent Technologies (A) has an average rating of overweight and mean price target of $161.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $115.35, Change: $+0.56, Percent Change: +0.49%

$A
Wire

Tigress Financial Cuts Monday.com Price Target to $165 From $310, Maintains Buy Rating

Monday.com (MNDY) has an average rating of overweight and mean price target of $105.65, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $78.88, Change: $+2.62, Percent Change: +3.44%

$MNDY
Wire

Update: Frontline Shares Fall After Q1 Adjusted Earnings Miss Estimates

(Updates with share movement in the headline and first paragraph)Frontline (FRO) shares were down 2.3% in Friday trading after the company reported Q1 adjusted earnings below analyst expectations.The company reported Q1 adjusted earnings Friday of $1.55 per diluted share, up from $0.18 a year earlier.Analysts polled by FactSet expected $1.65.Total revenue and other operating income for the quarter ended March 31 were $929.3 million, up from $428.1 million a year ago.Analysts surveyed by FactSet expected $579.6 million.Price: $37.56, Change: $-0.90, Percent Change: -2.34%

$FRO